-
Views
-
Cite
Cite
ANA-MARIA J. LENGYEL, GLORIA SHAFFER TANNENBAUM, Mechanisms of Calcitonin-Induced Growth Hormone (GH) Suppression: Roles of Somatostatin and GH-Releasing Factor, Endocrinology, Volume 120, Issue 4, 1 April 1987, Pages 1377–1383, https://doi.org/10.1210/endo-120-4-1377
Close - Share Icon Share
Abstract
Calcitonin (CT) binds to specific receptors in the hypothalamus and has been localized in the pituitary, suggesting a potential neuroendocrine role for this peptide. We and others have previously shown that CT given centrally markedly suppresses pulsatile GH secretion. However, the mechanism mediating this response remains to be elucidated. In the present study, we assessed the involvement of the two hypothalamic GH-regulatory peptides, somatostatin (SRIF) and GH-releasing factor (GRF), using a combination of in vivo and in vitro techniques. Six-hour GH secretory profiles were obtained from eight groups of freely moving rats bearing chronic intracerebroventricular (icv) and intraatrial cannulae. In four groups, salmon (s) CT (250 ng/10 μl) was administered icv, whereas the remaining four groups received either normal saline (NS) icv or sCT iv. Central injection of sCT caused a severe suppression in amplitude of spontaneous GH pulses compared to NS icv-treated control rats, whereas the same dose of sCT iv had no significant effect. Passive immunization of sCT icv-injected rats with a specific antiserum to SRIF failed to restore the amplitude of GH pulses to normal values. In addition, in vitro basal and 50 mM K+-stimulated SRIF release from incubated hypothalamic fragments was not altered by sCT in doses ranging from 10-10 to 10-6 M. The iv administration of a bolus of rat GRF (1–29)NH2 (1 μg) 1 h after sCT icv injection also failed to augment plasma GH levels compared to sCT iv-treated rats (16.6 ± 10.0 vs. 326.6 ± 63.6 ng/ml; P < 0.001) and NS icv controls (407.2 ± 145.4 ng/ ml; P < 0.01). Blood calcium levels decreased similarly 1 h after iv and icv sCT administration. These results demonstrate that: 1) sCT inhibits pulsatile GH secretion via a central nervous system site of action, 2) GH suppression induced by sCT is apparently not due solely to increased hypothalamic SRIF release, and 3) centrally administered sCT produces an acute loss of responsiveness of somatotrophs to GRF, which can be dissociated from peripheral blood calcium levels. (Endocrinology120: 1377–1383, 1987)
